Neurogen News

Biotechnology company Neurogen Corp. said Sunday it stopped a clinical trial of its insomnia candidate adipiplon because some patients experienced grogginess and memory loss.

Merriman Curhan Ford & Co. Presentation Operator Good day, ladies and gentlemen, and welcome to the first quarter Neurogen Corporation financial results conference call.

Array BioPharma Inc. , today announced that it has received an $80 million funding commitment from Deerfield Management, a leading healthcare - 05/05/2008 - 04:28 PM BRANFORD, Conn.-- --Neurogen Corporation , a ... via Business Wire

Mass High Tech: The Journal of New England Technology - Mass High Tech Neurogen Corp. via Bizjournals

MAXIMUS , a leading provider of government services, announced today that the California Department of Health Care Services has awarded the Company a - 04/09/2008 - 06:00 AM LAS VEGAS-- --You've heard the ... via Business Wire

“We're going to focus more of our financial resources - all of our financial resources - into our development portfolio”

Pfizer is a major investor.

Merck is a partner.

But Neurogen Corp. of Branford is barely hanging on.

After losing money for most of 20 years - more than $50 million last year - the drug development company has bet the house that a drastic restructuring will give investors enough promising information to keep them interested. A pioneer of Connecticut's biotech industry, Neurogen expects to close on a new $30.6 million financing deal in the coming days, it said this week.

The stock, which reached an all-time high of $47.37 in 2000, closed Thursday at $1.47 on the Nasdaq Stock Market. Shares are down 79 percent in the past 12 months, and on March 17 the company said its auditors have questioned its prospects as a going concern. Read more

Trimeris adds two to board [Raleigh/Durham] Biotech firm Neurogen Corp. said it plans to raise $30.6 million in a private placement and cut 45 workers to focus resources on clinical development. via Mass High Tech

March 24, 2008 Neurogen Corp.'s auditors added a "going concern" qualification to their opinion in the company's 2007 financial statements included in Neurogen's annual report on Form 10-K. Auditors add a going ... via Customer Interaction Solutions

NASDAQ's marketplace rules require NASDAQ-listed companies to publicly announce the receipt of an audit opinion containing a "going concern" qualification. via PR-inside.com

Stephen R. Davis, President & Chief Executive Officer Kenneth J. Sprenger, M.D., M.B.B.Ch - " Vice President, Clinical Development and Operations Analysts Katherine Xu - Credit Suisse Presentation Operator ... via Seeking Alpha

John LaMattina, former head of global research and development at Pfizer Inc has been appointed to the Company's Board of Directors. via PR-inside.com

Via Thomson Dialog NewsEdge) Feb. 9--BRANFORD -- Two days after announcing it is cutting its work force in half to focus more resources on clinical trials, Neurogen Corp. via Customer Interaction Solutions

“Over the next 12 months, we expect to generate important data in all five clinical programs”

Elaine Grimsell Dodge, 203-315-4615 edodge@nrgn.com Neurogen Corporation today updated the status of its later stage clinical portfolio and announced the future focus of its research efforts. via PR-inside.com

Neurogen Corp., a Branford biotech company, plans to eliminate 70 jobs, which is roughly half of its work force. via WFSB-TV Hartford

The Board of Directors of Dean & DeLuca announced today the appointment of Mark Daley as Chief Executive Officer. via Business Wire

NovaBay Pharmaceuticals Inc. hired Thomas Paulson as its chief financial officer. via The San Francisco Business Times

“I look forward to being part of the company's experienced management team as we strive to achieve our financial and product development objectives.”

Jan 10, 2008 - NovaBay Pharmaceuticals, Inc. , a biopharmaceutical company developing products for the treatment or prevention of a wide range of bacterial and viral infections, appointed Thomas J. Paulson as ... via Med Ad News

Neurogen Corp. reported before the bell that its third-quarter loss narrowed to $7.9 million, or $0.19 per share, better than Wall Street estimates of a $0.28 loss per share and compared with a loss of $10.9 ... via All Stories

RDATE:06112007 TheStreet.com Closed at $13.09. Today reported financial results for its third quarter and nine months ended September 30, 2007. via TMCnet

The poster, "Aplindore, a novel potent dopamine D receptor partial agonist is efficacious as a monotherapy or when combined with L-DOPA in treating motor disabilities in the MPTP -treated marmoset, a non-human ... via PR-inside.com